Palisade Bio Inc (PALI) Closing at $1.8 on Friday

Kiel Thompson

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

In other words, the price has increased by $0.00 from its previous closing price. On the day, 2.18 million shares were traded. PALI stock price reached its highest trading level at $1.8284 during the session, while it also had its lowest trading level at $1.75.

Ratios:

Our analysis of PALI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.78. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.00.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PALI now has a Market Capitalization of 268565792 and an Enterprise Value of 263191776.

Stock Price History:

The Beta on a monthly basis for PALI is 1.48, which has changed by -0.01098901 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, PALI has reached a high of $3.30, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is -1.45%, while the 200-Day Moving Average is calculated to be 75.35%.

Shares Statistics:

PALI traded an average of 8.16M shares per day over the past three months and 4138810 shares per day over the past ten days. A total of 149.00M shares are outstanding, with a floating share count of 139.74M. Insiders hold about 6.22% of the company’s shares, while institutions hold 28.40% stake in the company. Shares short for PALI as of 1763078400 were 7946168 with a Short Ratio of 0.97, compared to 1760486400 on 5920702. Therefore, it implies a Short% of Shares Outstanding of 7946168 and a Short% of Float of 5.33.

Earnings Estimates

Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating the stock of Palisade Bio Inc (PALI).The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.

Analysts are recommending an EPS of between -$0.18 and -$1.11 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.2, with 3.0 analysts recommending between -$0.09 and -$0.35.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.